Western Blot Lyme Testing Restrictions: What Changed and Why It Matters
Restrictions on Western blot Lyme testing highlight a critical issue in diagnosis: access to testing—and its limitations.
For years, clinicians relied on Western blot testing to clarify cases where Lyme disease was strongly suspected but screening tests were negative.
When access to this test was restricted, it exposed a larger problem: diagnosis depends not only on tests—but on how those tests are used.
These challenges are part of broader issues in Lyme disease test accuracy, where timing and immune response affect results.
When Access to Western Blot Testing Was Restricted
In 2014, a major U.S. laboratory implemented a policy that prevented physicians from ordering Western blot testing unless the initial screening test (ELISA or IFA) was positive or equivocal.
If the screening test was negative—even when clinical suspicion remained high—the Western blot was automatically denied.
This policy, implemented by :contentReference[oaicite:0]{index=0}, reflected broader efforts to standardize Lyme disease testing.
For clinicians treating patients in endemic areas, this created a significant barrier to diagnosis.
Why Physicians Ordered Western Blot Independently
Clinicians often ordered Western blot testing even when screening tests were negative due to known limitations in early Lyme disease detection.
Whole-cell ELISA sensitivity in patients with erythema migrans (EM rash) ranges from 33–49%. The FDA-approved C6 peptide test showed 37% sensitivity in well-defined cases and 66.5% in EM rash patients.
These findings demonstrate that screening tests can miss a substantial number of early Lyme cases.
Western blot provided additional diagnostic insight:
- IgM bands may persist after infection
- IgG bands may be present even when screening tests are negative
For experienced clinicians, Western blot was often an essential diagnostic tool—not optional.
Why Testing Access Was Restricted
Restrictions reflected broader concerns within the diagnostic community:
- Technical complexity: Western blot requires visual interpretation, which can vary between laboratories
- Surveillance vs clinical use: CDC two-tier criteria were designed for population surveillance, not individual diagnosis
- Standardization pressure: Automated immunoassays provide faster and more consistent results
- Early infection limitations: Western blot may remain negative in the first weeks of illness
These concerns supported standardization—but did not resolve real-world diagnostic limitations.
The Impact on Patient Care
Restrictions created immediate challenges:
- Delayed diagnosis
- Increased costs from alternative laboratories
- Reduced access for patients with high clinical suspicion
This reflects a central tension in Lyme disease care: policies designed for consistency may not fit complex clinical presentations.
These delays are often seen in delayed Lyme disease diagnosis, where early testing fails to capture evolving disease.
What Changed: Current Access
Access to Western blot testing has since been restored.
Physicians can now order Western blot testing regardless of screening results.
This change reflects recognition that clinical decision-making requires flexibility.
At the same time, Modified Two-Tier Testing (MTTT) has been introduced, using two enzyme immunoassays instead of ELISA followed by Western blot.
Despite these changes, Western blot remains valuable for its detailed antigen-specific information.
Why Testing Alone Is Not Enough
All antibody-based tests share a fundamental limitation: they depend on the immune response.
They may not reliably detect:
- Early infection (before antibodies develop)
- Immune suppression
- Antibiotic-altered immune responses
This means testing supports—but does not define the diagnosis.
Clinical judgment remains essential, particularly when symptoms evolve or testing is inconclusive.
Frequently Asked Questions
Can Western blot testing be ordered now?
Yes. Physicians can order it regardless of screening results.
Why was access restricted?
Due to concerns about variability, standardization, and adherence to two-tier testing protocols.
Is Western blot more accurate than ELISA?
It provides different information (band patterns), but both tests have limitations—especially in early infection.
What is Modified Two-Tier Testing?
A newer approach using two immunoassays instead of ELISA plus Western blot.
Which test should be used?
This depends on clinical judgment. No test replaces careful evaluation of symptoms and exposure history.
Clinical Takeaway
Restrictions on Western blot testing highlight a fundamental truth: access to testing matters—but testing limitations matter more.
Early Lyme disease—the stage when treatment is most effective—is also when testing is least reliable.
Restoring access improved flexibility—but did not resolve the underlying diagnostic challenge.
Lyme disease remains a clinical diagnosis supported by laboratory findings—not defined by them.
When symptoms and exposure suggest infection, care should not be delayed while waiting for tests to confirm what biology has not yet revealed.
Related Reading
- Lyme Disease Testing and Diagnosis
- Understanding Lyme Disease Test Accuracy
- Beyond CDC Testing Guidelines
- Don’t Wait for a Positive Test
- Why I Treated Despite Negative Tests
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
